1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Angina Pectoris Treatment Market
2.2. Global Angina Pectoris Treatment Market, By Drug Class, 2023 (US$ Million)
2.3. Global Angina Pectoris Treatment Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Angina Pectoris Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Angina Pectoris Treatment Market Vendors
3.2. Strategies Adopted by Angina Pectoris Treatment Market Vendors
3.3. Key Industry Strategies
4. Angina Pectoris Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Angina Pectoris Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Antiplatelet agents
5.3.2. Beta-adrenergic blocking agents
5.3.3. Calcium channel blockers
5.3.4. Short & Long – acting Nitroglycerines
5.3.5. Angiotensin-converting enzyme inhibitors
5.3.6. Anti-ischemic agents
5.3.7. Pipeline Analysis
5.3.7.1. Projected sales of Phase III Drugs estimated till 2030 (US$ Mn)
5.3.7.1.1. Dantonic/T89
5.3.7.1.2. RANCAD
5.3.7.1.3. Cilostazol
5.3.7.1.4. Bococizumab
5.3.7.1.5. Ticagrelor
5.3.7.1.6. Auto-CD34+ cells
5.3.7.1.7. Alirocumab
5.3.7.2. Tabular Representation of Phase II and I Drugs


6. North America Angina Pectoris Treatment Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
6.3.Angina Pectoris Treatment Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)

7. UK and European Union Angina Pectoris Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.Angina Pectoris Treatment Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)

8. Asia Pacific Angina Pectoris Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.Angina Pectoris Treatment Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)

9. Latin America Angina Pectoris Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.3.Angina Pectoris Treatment Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)

10. Middle East and Africa Angina Pectoris Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.3.Angina Pectoris Treatment Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Angina Pectoris Treatment Market: By Drug Class, 2022-2032, USD (Million)

11. Company Profile
11.1. Abbott Laboratories Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Astra Zeneca plc
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Bayer AG
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Bristol-Myers Squibb Company
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. F. Hoffmann-La Roche Ltd.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Forest Laboratories Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Gilead Sciences, Inc.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. GlaxoSmithKline plc
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Novartis AG
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Pfizer Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Sanofi SA
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives